Capital Performance Advisors LLP Protalix Bio Therapeutics, Inc. Transaction History
Capital Performance Advisors LLP
- $259 Million
- Q1 2024
A detailed history of Capital Performance Advisors LLP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 26,258 shares of PLX stock, worth $27,570. This represents 0.01% of its overall portfolio holdings.
Number of Shares
26,258
Previous 25,975
1.09%
Holding current value
$27,570
Previous $46,000
28.26%
% of portfolio
0.01%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding PLX
# of Institutions
66Shares Held
9.27MCall Options Held
40.6KPut Options Held
10.1K-
Black Rock Inc. New York, NY3.31MShares$3.48 Million0.0% of portfolio
-
State Street Corp Boston, MA827KShares$867,9100.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny825KShares$865,9350.0% of portfolio
-
Geode Capital Management, LLC Boston, MA754KShares$791,8150.0% of portfolio
-
Gsa Capital Partners LLP London, X0494KShares$518,2490.05% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $52.2M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...